When blood cell precursors acquire mutations, they can form excessive immature cells and lead to blood cancer. We study the mechanisms behind the acquisition of such mutations. We explore new therapeutic avenues by inhibiting growth factor receptors and activators called JAKs, and by studying mechanisms of resistance to chemotherapy.